ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Join Dr. Eric Singhi as he discusses future trends in 1L KRAS G12Cm mNSCLC including adagrasib (Video 3/3) {{LINK}}
    Sign up to watch this video

    Free access to all Sound Bites content

    Join Dr. Eric Singhi as he discusses future trends in 1L KRAS G12Cm mNSCLC including adagrasib (Video 3/3) {{LINK}}

    Published on: May 27, 2025

    E

    Eric Singhi , MD

    Medical Professional

    KRYSTAL-7 Trial Design, Efficacy and Safety

    Related Videos
    Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC (Video 1/3)

    Dr. Charu Aggarwal discusses the efficacy of datopotamab deruxtecan in pretreated mNSCLC (Video 1/3)

    Charu Aggarwal, MD
    Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

    Dr. Eric Singhi reviews 5-year efficacy of cemiplimab + chemotherapy in aNSCLC (Video 1/3)

    Eric Singhi , MD
    Dr. Joshua Zeidner reviews the data for revumenib in patients with NPM1-mutated AML (Video 3/3)

    Dr. Joshua Zeidner reviews the data for revumenib in patients with NPM1-mutated AML (Video 3/3)

    Joshua Zeidner, MD
    Dr. Hossein Borghaei describes the safety of nivo/ipi + chemo in patients with mNSCLC and the efficacy in patients who discontinue early. (Video 3/3)

    Dr. Hossein Borghaei describes the safety of nivo/ipi + chemo in patients with mNSCLC and the efficacy in patients who discontinue early. (Video 3/3)

    Hossein Borghaei, MD
    Dr. Arvind Dasari gives an overview of ctDNA with a focus on why the data from Galaxy and Bespoke-CRC was pooled for surveillance (Video 1/3)

    Dr. Arvind Dasari gives an overview of ctDNA with a focus on why the data from Galaxy and Bespoke-CRC was pooled for surveillance (Video 1/3)

    Arvind Dasari, MD
    Dr. Melissa Johnson describes the safety of atezolizumab + lurbinectedin maintenance therapy in 1L ES-SCLC. (Video 3/3)

    Dr. Melissa Johnson describes the safety of atezolizumab + lurbinectedin maintenance therapy in 1L ES-SCLC. (Video 3/3)

    Melissa Johnson